XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (128,659) $ (133,055)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 812 652
Inventory obsolescence 238 0
Stock-based compensation expense 26,848 19,468
Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs 43,935 36,725
Amortization of premium/discount on investments (4,217) (88)
Loss on extinguishment of debt (29,019) 0
Changes in operating assets and liabilities:    
Receivables (6,968) (12,343)
Inventory 1,029 (7,589)
Prepaid expenses and other assets (1,484) (1,050)
Accounts payable and accrued expenses (27,414) (8,463)
Deferred revenue 535 186
Net cash used in operating activities (66,326) (105,557)
Cash flows from investing activities:    
Acquisitions of property and equipment (627) (650)
Purchase of investments (233,530) (139,260)
Sales and maturities of investments 108,013 4,000
Net cash used in investing activities (126,144) (135,910)
Cash flows from financing activities:    
Net proceeds from common stock issued under stock-based compensation plans 7,031 7,503
Proceeds from issuance of long-term debt, total 300,000 0
Repayment of Athyrium secured term loans principal (240,452) 0
Prepayment and repayment fees on Athyrium secured term loans (21,261) 0
Payment of debt issuance costs on Pharmakon Tranche A term loan (10,885) 0
Net cash provided by financing activities 34,433 7,503
Effect of exchange rate on cash, cash equivalents, and restricted cash (413) 249
Decrease in cash, cash equivalents and restricted cash (158,450) (233,715)
Cash, cash equivalents and restricted cash at beginning of period 306,239 507,734
Cash, cash equivalents and restricted cash at end of period $ 147,789 $ 274,019